Evidence map›Paper›PMID 39528488›Full record

ArticleBlood cancer journal2024

Genetically determined telomere length in monoclonal gammopathy of undetermined significance, multiple myeloma risk and outcome.

Matteo Giaccherini, Alyssa I Clay-Gilmour, Romano Liotti, Angelica Macauda, Manuel Gentiluomo, Elizabeth E Brown, Mitchell J Machiela, Stephen J Chanock, Michelle A T Hildebrandt, Aaron D Norman and 15 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Matteo Giaccherini *Department of Biology, University of Pisa, Pisa, Italy.ORCID http://orcid.org/0000-0002-0363-6632
Alyssa I Clay-Gilmour *Department of Biostatistics & Epidemiology, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA.ORCID http://orcid.org/0000-0001-9998-4879
Romano LiottiDepartment of Biology, University of Pisa, Pisa, Italy.
Angelica MacaudaGenomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Manuel GentiluomoDepartment of Biology, University of Pisa, Pisa, Italy.
Elizabeth E BrownDepartment of Pathology, Heersink School of Medicine, University of Alabama, Birmingham, AL, USA.
Mitchell J MachielaDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Stephen J ChanockDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-2324-3393
Michelle A T HildebrandtDivision of Cancer Medicine, Department of Lymphoma - Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Aaron D NormanDivision of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Elisabet ManasanchDivision of Cancer Medicine, Department of Lymphoma - Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-0857-176X
S Vincent RajkumarDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-5862-1833
Jonathan N HofmannDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-1043-5812
Sonja I BerndtDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0001-5230-0652
Parveen BhattiCancer Control Research, BC Cancer, Vancouver, BC, Canada.
Graham G GilesCancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0003-4946-9099
Elad ZivDepartment of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
Shaji K KumarDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-5392-9284
Nicola J CampDivision of Hematology and Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.ORCID http://orcid.org/0000-0002-4788-1998
Wendy CozenDivision of Hematology/Oncology, Department of Medicine, School of Medicine, Department of Pathology, School of Medicine, Susan and Henry Samueli College of Health Sciences, Chao Family Comprehensive Cancer Center, University of California at Irvine, Irvine, CA, USA.
Susan L SlagerDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-5173-4712
Federico CanzianGenomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0002-4261-4583
Federica Gemignani *Department of Biology, University of Pisa, Pisa, Italy.
Celine M Vachon *Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-1962-9322
Daniele Campa *Department of Biology, University of Pisa, Pisa, Italy. daniele.campa@unipi.it.ORCID http://orcid.org/0000-0003-3220-9944

Funding

Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Yi Lin · 2015 to 2026
$25.5M
NCI NIH HHS P50 CA186781
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39528488
PMCPMC11554786

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.